NCT06900595 2026-03-18
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
12 trialsNCT05286814 2026-02-24
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06006013 2026-02-18
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Emory University
Phase 2 Recruiting
NCT06066333 2026-02-03
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06333314 2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2 Recruiting
NCT07085572 2025-10-06
INTERVAL
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Recruiting
NCT03127774 2025-10-03
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Columbia University
Phase 2 Recruiting
NCT06831175 2025-06-03
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
West China Hospital
Phase 2 Recruiting
NCT06587802 2025-04-29
Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT05563467 2025-04-02
PEMBR-01
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Recruiting
NCT05913427 2024-08-01
PESETA
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Recruiting
NCT04318730 2024-07-17
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
West China Hospital
Phase 2 Recruiting